Other formats:
BibTeX
LaTeX
RIS
@proceedings{2247558,
author = {Taylor, Peter and Behrens, Frank and Mease, Philip J. and Wetzel, Dieter and Peloso, Paul and Brun, Nicolai and Wiens, Brian and Brandtjuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and Martin, Nadia AbdelandKader and de Vlam, Kurt},
keywords = {Izokibep; IL-17A inhibitor; patient outcomes; psoriatic arthriris; clinical trial},
language = {eng},
title = {Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis},
url = {https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/},
year = {2022}
}
TY - CONF
ID - 2247558
AU - Taylor, Peter - Behrens, Frank - Mease, Philip J. - Wetzel, Dieter - Peloso, Paul - Brun, Nicolai - Wiens, Brian - Brandtjuergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Martin, Nadia Abdel-Kader - de Vlam, Kurt
PY - 2022
TI - Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
KW - Izokibep
KW - IL-17A inhibitor
KW - patient outcomes
KW - psoriatic arthriris
KW - clinical trial
UR - https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/
N2 - Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a key driver of the PsA disease process, which greatly impacts patients’ physical function, vitality, social participation, mood, and quality of life. Here, we report 16-week results of izokibep on patient-reported outcomes (PROs) in adult patients with active PsA.
ER -
TAYLOR, Peter, Frank BEHRENS, Philip J. MEASE, Dieter WETZEL, Paul PELOSO, Nicolai BRUN, Brian WIENS, Jan BRANDTJUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Kurt DE VLAM. \textit{Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis}. 2022. ISSN~2326-5191.
|
